Patients considering maintenance lurbinectedin with atezolizumab need comprehensive information about potential adverse effects to make informed treatment decisions with their hea ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...

The European Medicines Agency (EMA) has approved Ryzneuta (efbemalenograstim alfa) as a treatment to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults treated with ...

X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...

(RTTNews) - X4 Pharmaceuticals, Inc. (XFOR), Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia ...